Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

N/A
3(60.0%)
Phase 2
2(40.0%)
5Total
N/A(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02682992Not ApplicableCompleted

Low-Level Laser Therapy for Prevention of Oral Mucositis

Role: lead

NCT01360593Phase 2Completed

Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma

Role: lead

NCT01104922Phase 2Completed

Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck

Role: lead

NCT02516969Not ApplicableCompleted

Surgery With or Without Adjuvant Stereotactic Body Radiotherapy

Role: lead

NCT01357525Not ApplicableCompleted

SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma

Role: lead

All 5 trials loaded